Clinical Trial Detail

NCT ID NCT01307267
Title A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Pfizer
Indications

head and neck squamous cell carcinoma

diffuse large B-cell lymphoma

follicular lymphoma

Advanced Solid Tumor

non-Hodgkin lymphoma

melanoma

lung non-small cell carcinoma

B-cell lymphoma

renal cell carcinoma

Therapies

Rituximab + Utomilumab

Utomilumab

Age Groups: senior adult

No variant requirements are available.